Publication

Serum carbonic anhydrase IX during first-line therapy of ovarian cancer

Woelber, L., Mueller, V., Eulenburg, C., Schwarz, J., Carney, W., Jaenicke, F., Milde-Langosch, K. & Mahner, S., May-2010, In : Gynecologic Oncology. 117, 2, p. 183-188 6 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Woelber, L., Mueller, V., Eulenburg, C., Schwarz, J., Carney, W., Jaenicke, F., ... Mahner, S. (2010). Serum carbonic anhydrase IX during first-line therapy of ovarian cancer. Gynecologic Oncology, 117(2), 183-188. https://doi.org/10.1016/j.ygyno.2009.11.029

Author

Woelber, Linn ; Mueller, Volkmar ; Eulenburg, Christine ; Schwarz, Joerg ; Carney, Walter ; Jaenicke, Fritz ; Milde-Langosch, Karin ; Mahner, Sven. / Serum carbonic anhydrase IX during first-line therapy of ovarian cancer. In: Gynecologic Oncology. 2010 ; Vol. 117, No. 2. pp. 183-188.

Harvard

Woelber, L, Mueller, V, Eulenburg, C, Schwarz, J, Carney, W, Jaenicke, F, Milde-Langosch, K & Mahner, S 2010, 'Serum carbonic anhydrase IX during first-line therapy of ovarian cancer', Gynecologic Oncology, vol. 117, no. 2, pp. 183-188. https://doi.org/10.1016/j.ygyno.2009.11.029

Standard

Serum carbonic anhydrase IX during first-line therapy of ovarian cancer. / Woelber, Linn; Mueller, Volkmar; Eulenburg, Christine; Schwarz, Joerg; Carney, Walter; Jaenicke, Fritz; Milde-Langosch, Karin; Mahner, Sven.

In: Gynecologic Oncology, Vol. 117, No. 2, 05.2010, p. 183-188.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Woelber L, Mueller V, Eulenburg C, Schwarz J, Carney W, Jaenicke F et al. Serum carbonic anhydrase IX during first-line therapy of ovarian cancer. Gynecologic Oncology. 2010 May;117(2):183-188. https://doi.org/10.1016/j.ygyno.2009.11.029


BibTeX

@article{de412390c0a0466e8315f9b8f21c96ca,
title = "Serum carbonic anhydrase IX during first-line therapy of ovarian cancer",
abstract = "Objective. Carbonic anhydrase IX (CAIX) is primarily involved in maintaining the extracellular pH. It is overexpressed in a variety of tumors including ovarian cancer. To evaluate the potential prognostic and predictive role of serum CAIX for therapy response in ovarian cancer, we analyzed longitudinal serum samples.Methods. One hundred forty-eight serum samples from 37 patients with primary epithelial ovarian cancer were analyzed. Samples were prospectively collected at 4 time points: (1) before radical surgery, (2) after surgery and before platinum/taxane chemotherapy, (3) during chemotherapy, and (4) after chemotherapy. Serum CAIX was quantified by ELISA and expression in tumor tissue was verified by immunohistochemistry. Correlation with response and clinical outcome as well as the tumor marker CA-125 was analyzed.Results. Serum concentration of CAIX ranged between 30 and 1687 pg/mL and showed no significant changes during first-line therapy (median level before and after surgery 204 and 198 pg/mL, during and after chemotherapy 175 and 181 pg/mL). There was no association between serum CAIX and progression-free or overall survival. CA-125 decreased significantly after surgery (median serum level before and after surgery 413 and 84 kU/L, pNo intermarker correlation was observed.Conclusions. CAIX is upregulated in ovarian cancer and serum CAIX could be a marker to stratify patients for therapy response. However, CAIX serum levels did not change significantly during first-line therapy and were not prognostically relevant. Based on the findings of the current study, CAIX cannot be recommended for therapy monitoring in this context. (C) 2009 Elsevier Inc. All rights reserved.",
keywords = "Carbonic anhydrase, Ovarian cancer, Biomarker, Therapy monitoring, RENAL-CELL CARCINOMA, MONOCLONAL-ANTIBODY, CLINICAL-TRIAL, PROGNOSTIC-FACTOR, TUMOR HYPOXIA, CA-IX, EXPRESSION, MARKER, SURVIVAL, CA-125",
author = "Linn Woelber and Volkmar Mueller and Christine Eulenburg and Joerg Schwarz and Walter Carney and Fritz Jaenicke and Karin Milde-Langosch and Sven Mahner",
year = "2010",
month = "5",
doi = "10.1016/j.ygyno.2009.11.029",
language = "English",
volume = "117",
pages = "183--188",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "ACADEMIC PRESS INC ELSEVIER SCIENCE",
number = "2",

}

RIS

TY - JOUR

T1 - Serum carbonic anhydrase IX during first-line therapy of ovarian cancer

AU - Woelber, Linn

AU - Mueller, Volkmar

AU - Eulenburg, Christine

AU - Schwarz, Joerg

AU - Carney, Walter

AU - Jaenicke, Fritz

AU - Milde-Langosch, Karin

AU - Mahner, Sven

PY - 2010/5

Y1 - 2010/5

N2 - Objective. Carbonic anhydrase IX (CAIX) is primarily involved in maintaining the extracellular pH. It is overexpressed in a variety of tumors including ovarian cancer. To evaluate the potential prognostic and predictive role of serum CAIX for therapy response in ovarian cancer, we analyzed longitudinal serum samples.Methods. One hundred forty-eight serum samples from 37 patients with primary epithelial ovarian cancer were analyzed. Samples were prospectively collected at 4 time points: (1) before radical surgery, (2) after surgery and before platinum/taxane chemotherapy, (3) during chemotherapy, and (4) after chemotherapy. Serum CAIX was quantified by ELISA and expression in tumor tissue was verified by immunohistochemistry. Correlation with response and clinical outcome as well as the tumor marker CA-125 was analyzed.Results. Serum concentration of CAIX ranged between 30 and 1687 pg/mL and showed no significant changes during first-line therapy (median level before and after surgery 204 and 198 pg/mL, during and after chemotherapy 175 and 181 pg/mL). There was no association between serum CAIX and progression-free or overall survival. CA-125 decreased significantly after surgery (median serum level before and after surgery 413 and 84 kU/L, pNo intermarker correlation was observed.Conclusions. CAIX is upregulated in ovarian cancer and serum CAIX could be a marker to stratify patients for therapy response. However, CAIX serum levels did not change significantly during first-line therapy and were not prognostically relevant. Based on the findings of the current study, CAIX cannot be recommended for therapy monitoring in this context. (C) 2009 Elsevier Inc. All rights reserved.

AB - Objective. Carbonic anhydrase IX (CAIX) is primarily involved in maintaining the extracellular pH. It is overexpressed in a variety of tumors including ovarian cancer. To evaluate the potential prognostic and predictive role of serum CAIX for therapy response in ovarian cancer, we analyzed longitudinal serum samples.Methods. One hundred forty-eight serum samples from 37 patients with primary epithelial ovarian cancer were analyzed. Samples were prospectively collected at 4 time points: (1) before radical surgery, (2) after surgery and before platinum/taxane chemotherapy, (3) during chemotherapy, and (4) after chemotherapy. Serum CAIX was quantified by ELISA and expression in tumor tissue was verified by immunohistochemistry. Correlation with response and clinical outcome as well as the tumor marker CA-125 was analyzed.Results. Serum concentration of CAIX ranged between 30 and 1687 pg/mL and showed no significant changes during first-line therapy (median level before and after surgery 204 and 198 pg/mL, during and after chemotherapy 175 and 181 pg/mL). There was no association between serum CAIX and progression-free or overall survival. CA-125 decreased significantly after surgery (median serum level before and after surgery 413 and 84 kU/L, pNo intermarker correlation was observed.Conclusions. CAIX is upregulated in ovarian cancer and serum CAIX could be a marker to stratify patients for therapy response. However, CAIX serum levels did not change significantly during first-line therapy and were not prognostically relevant. Based on the findings of the current study, CAIX cannot be recommended for therapy monitoring in this context. (C) 2009 Elsevier Inc. All rights reserved.

KW - Carbonic anhydrase

KW - Ovarian cancer

KW - Biomarker

KW - Therapy monitoring

KW - RENAL-CELL CARCINOMA

KW - MONOCLONAL-ANTIBODY

KW - CLINICAL-TRIAL

KW - PROGNOSTIC-FACTOR

KW - TUMOR HYPOXIA

KW - CA-IX

KW - EXPRESSION

KW - MARKER

KW - SURVIVAL

KW - CA-125

U2 - 10.1016/j.ygyno.2009.11.029

DO - 10.1016/j.ygyno.2009.11.029

M3 - Article

VL - 117

SP - 183

EP - 188

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -

ID: 34213307